Serena Desiderio was diagnosed with muscular dystrophy just a few years ago in high school at age 14. She is now the first ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...

Request a sample and discover the recent advances in myotonic dystrophy treatment drugs @ Myotonic Dystrophy Pipeline Report The myotonic dystrophy pipeline report provides detailed profiles of ...

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global ...

Other clinical-stage candidates that Sarepta will gain access to include ARO-DUX4, a potential treatment for facioscapulohumeral muscular dystrophy and ARO-MMP7 ... complementing its work developing ...

Sarepta Therapeutics Inc. has a plan in place to significantly expand the diseases it treats beyond Duchenne muscular ...

The program is currently being tested as a treatment for a genetic muscle ... and complement existing work in Duchenne muscular dystrophy and limb-girdle muscular dystrophies and gene therapy ...

which currently includes treatments for Duchenne muscular dystrophy and limb-girdle muscular dystrophies. The deal encompasses four clinical-stage programs, including therapies for ...

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of ... which includes ...